MP34-20 METASTASIS-FREE SURVIVAL (MFS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH PROSTATE-SPECIFIC ANTIGEN (PSA) DECLINE TO < 0.2 NG/ML FOLLOWING APALUTAMIDE (APA) TREATMENT: POST HOC RESULTS FROM THE PHASE 3 SPARTAN STUDY
Notice bibliographique
Résumé
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) IV (MP34)1 Apr 2019MP34-20 METASTASIS-FREE SURVIVAL (MFS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH PROSTATE-SPECIFIC ANTIGEN (PSA) DECLINE TO < 0.2 NG/ML FOLLOWING APALUTAMIDE (APA) TREATMENT: POST HOC RESULTS FROM THE PHASE 3 SPARTAN STUDY Julie N. Graff*, Fred Saad, Boris A. Hadaschik, Paul N. Mainwaring, Hiroji Uemura, Simon Chowdhury, Stéphane Oudard, David Olmos, Ji Youl Lee, Angela Lopez-Gitlitz, Amitabha Bhaumik, Anil Londhe, Shinta Cheng, Mary B. Todd, Matthew R. Smith, and Eric J. Small Julie N. Graff*Julie N. Graff* More articles by this author , Fred SaadFred Saad More articles by this author , Boris A. HadaschikBoris A. Hadaschik More articles by this author , Paul N. MainwaringPaul N. Mainwaring More articles by this author , Hiroji UemuraHiroji Uemura More articles by this author , Simon ChowdhurySimon Chowdhury More articles by this author , Stéphane OudardStéphane Oudard More articles by this author , David OlmosDavid Olmos More articles by this author , Ji Youl LeeJi Youl Lee More articles by this author , Angela Lopez-GitlitzAngela Lopez-Gitlitz More articles by this author , Amitabha BhaumikAmitabha Bhaumik More articles by this author , Anil LondheAnil Londhe More articles by this author , Shinta ChengShinta Cheng More articles by this author , Mary B. ToddMary B. Todd More articles by this author , Matthew R. SmithMatthew R. Smith More articles by this author , and Eric J. SmallEric J. Small More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000555927.90500.b0AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: APA, a next-generation androgen receptor inhibitor, added to androgen deprivation therapy (ADT) improved MFS by > 2 years (median 40.5 vs 16.2 mo; p < 0.0001) in high-risk pts with nmCRPC in the phase 3 SPARTAN study. In this post hoc analysis, we examined clinical outcomes in APA-treated pts whose PSA declined to < 0.2 ng/mL. METHODS: In SPARTAN, pts with nmCRPC with PSA doubling time of ≤ 10 months were randomized 2:1 to APA (240 mg QD) + ADT or placebo (PBO) + ADT. MFS, time to metastasis (mets) (TTM), and location of mets were evaluated as a function of PSA status (PSA decline to < 0.2 ng/mL at any time during the study, vs PSA not declining to < 0.2 ng/mL). Cox proportional hazard analysis estimated HRs and 95% CI. RESULTS: Following treatment with APA, PSA declined to < 0.2 ng/mL in 319/806 (40%) pts; 1 PBO pt had a decline in PSA to < 0.2 ng/mL. APA pts with a PSA decline to < 0.2 ng/mL had a 76% risk reduction for MFS (Figure) and TTM. Compared with pts who received PBO, the APA pts with PSA that declined to < 0.2 ng/mL had an 88% risk reduction for MFS and TTM. When mets developed, depth of PSA decline (to < 0.2 ng/mL vs not reaching < 0.2 ng/mL) was not associated with location of mets (bone: 53% vs 58%; nodes: 27% vs 31%). CONCLUSIONS: In nmCRPC pts treated with APA, a PSA decline to < 0.2 ng/mL occurred in 40% of pts, and was associated with an improvement in clinical end points, including MFS. Depth of PSA decline was not associated with a specific metastatic pattern. Source of Funding: Janssen Research & Development Portland, OR; Montréal, Canada; Essen, Germany; Brisbane, Australia; Yokohama, Japan; London, United Kingdom; Paris, France; Madrid, Spain; Seoul, Korea, Republic of; Los Angeles, CA; Yardley, PA; Titusville, NJ; Raritan, NJ; Boston, MA; San Francisco, CA© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e503-e503 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Julie N. Graff* More articles by this author Fred Saad More articles by this author Boris A. Hadaschik More articles by this author Paul N. Mainwaring More articles by this author Hiroji Uemura More articles by this author Simon Chowdhury More articles by this author Stéphane Oudard More articles by this author David Olmos More articles by this author Ji Youl Lee More articles by this author Angela Lopez-Gitlitz More articles by this author Amitabha Bhaumik More articles by this author Anil Londhe More articles by this author Shinta Cheng More articles by this author Mary B. Todd More articles by this author Matthew R. Smith More articles by this author Eric J. Small More articles by this author Expand All Advertisement PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,001 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».